The hepatoselective glucokinase activator PF-04991532 ameliorates hyperglycemia without causing hepatic steatosis in diabetic rats

PLoS ONE

Volumn 9, Issue 5, 2014, Pages

  Erion, Derek M ^a   Lapworth, Amanda ^a   Amor, Paul A ^a   Bai, Guoyun ^a   Vera, Nicholas B ^a   Clark, Ronald W ^a   Yan, Qingyun ^a   Zhu, Yimin ^a   Ross, Trenton T ^a   Purkal, Julie ^a   Gorgoglione, Matthew ^a   Zhang, Guodong ^a   Bonato, Vinicius ^a   Baker, Levenia ^a   Barucci, Nicole ^a   D'Aquila, Theresa ^a   Robertson, Alan ^a   Aiello, Robert J ^a   Yan, Jiangli ^a   Trimmer, Jeff ^a   Rolph, Timothy P ^a   Pfefferkorn, Jeffrey A ^a   more..

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE PHOSPHATE; ENZYME ACTIVATOR; GLUCOKINASE; GLUCOSE; GLUCOSE 6 PHOSPHATE; INSULIN; PF 04991532; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; 6-(3-CYCLOPENTYL-2-(4-TRIFLUOROMETHYL)-1H-IMIDAZOL-1-YL)PROPANAMIDO)NICOTINIC ACID; IMIDAZOLE DERIVATIVE; NICOTINIC ACID;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; DRUG SELECTIVITY; DRUG STRUCTURE; ENZYME ACTIVATION; ENZYME ACTIVITY; FATTY LIVER; GLUCONEOGENESIS; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; GLUCOSE OXIDATION; GLUCOSE TRANSPORT; GLYCEMIC CONTROL; HYPERGLYCEMIA; INSULIN BLOOD LEVEL; LIPID METABOLISM; MALE; NONHUMAN; ORAL GLUCOSE TOLERANCE TEST; RAT; TRIACYLGLYCEROL BLOOD LEVEL; ANALOGS AND DERIVATIVES; ANIMAL; ANTIBODY SPECIFICITY; CHEMICALLY INDUCED; COMPLICATION; DRUG EFFECTS; ENZYMOLOGY; EXPERIMENTAL DIABETES MELLITUS; LIVER; LIVER CELL; METABOLISM; NONALCOHOLIC FATTY LIVER; PATHOLOGY;

ANIMALS; DIABETES MELLITUS, EXPERIMENTAL; ENZYME ACTIVATORS; GLUCOKINASE; GLUCOSE; HEPATOCYTES; HYPERGLYCEMIA; IMIDAZOLES; LIVER; MALE; NIACIN; NON-ALCOHOLIC FATTY LIVER DISEASE; ORGAN SPECIFICITY; RATS;

EID: 84901474485     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0097139     Document Type: Article

References (54)

1. Erion DM, Shulman GI (2010) Diacylglycerol-mediated insulin resistance. Nat Med 16: 400-402.
2. DeFronzo RA, Bonadonna RC, Ferrannini E (1992) Pathogenesis of NIDDM. A balanced overview. Diabetes Care 15: 318-368.
3. Reaven GM, Chen YD, Golay A, Swislocki AL, Jaspan JB (1987) Documentation of hyperglucagonemia throughout the day in nonobese and obese patients with noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 64: 106-110. (Pubitemid 17015886)
4. Matschinsky FM (2009) Assessing the potential of glucokinase activators in diabetes therapy. Nat Rev Drug Discov 8: 399-416.
5. Matschinsky FM (1996) Banting Lecture 1995. A lesson in metabolic regulation inspired by the glucokinase glucose sensor paradigm. Diabetes 45: 223-241.
6. Gloyn AL, Noordam K, Willemsen MA, Ellard S, Lam WW, et al. (2003) Insights into the biochemical and genetic basis of glucokinase activation from naturally occurring hypoglycemia mutations. Diabetes 52: 2433-2440. (Pubitemid 37059517)
7. Cuesta-Munoz AL, Huopio H, Otonkoski T, Gomez-Zumaquero JM, Nanto-Salonen K, et al. (2004) Severe persistent hyperinsulinemic hypoglycemia due to a de novo glucokinase mutation. Diabetes 53: 2164-2168. (Pubitemid 38970771)
8. Froguel P, Vaxillaire M, Sun F, Velho G, Zouali H, et al. (1992) Close linkage of glucokinase locus on chromosome 7p to early-onset non-insulin-dependent diabetes mellitus. Nature 356: 162-164.
9. Hattersley AT, Turner RC, Permutt MA, Patel P, Tanizawa Y, et al. (1992) Linkage of type 2 diabetes to the glucokinase gene. Lancet 339: 1307-1310.
10. Meininger GE, Scott R, Alba M, Shentu Y, Luo E, et al. (2011) Effects of MK-0941, a novel glucokinase activator, on glycemic control in insulin-treated patients with type 2 diabetes. Diabetes Care 34: 2560-2566.
11. Wilding JP, Leonsson-Zachrisson M, Wessman C, Johnsson E (2013) Doseranging study with the glucokinase activator AZD1656 in patients with type 2 diabetes mellitus on metformin. Diabetes Obes Metab.
12. Kiyosue A, Hayashi N, Komori H, Leonsson-Zachrisson M, Johnsson E (2013) Dose-ranging study with the glucokinase activator AZD1656 as monotherapy in Japanese patients with type 2 diabetes mellitus. Diabetes Obes Metab.
13. Pfefferkorn JA (2013) Strategies for the design of hepatoselective glucokinase activators to treat type 2 diabetes. Expert Opin Drug Discov 8: 319-330.
14. Bebernitz GR, Beaulieu V, Dale BA, Deacon R, Duttaroy A, et al. (2009) Investigation of functionally liver selective glucokinase activators for the treatment of type 2 diabetes. J Med Chem 52: 6142-6152.
15. Mookhtiear KA, Umrani D, De S, Bhuniva D (2012) The liver directed/pancreas-sparing pharmacokinetic profile of GKM-001, a glucokinase modulator with robust glucose lowering properties and low hypoglycemia risk. 72nd American Diabetes Association Meeting, Philadelphia, PA.
16. Agius L (2008) Glucokinase and molecular aspects of liver glycogen metabolism. Biochem J 414: 1-18.
17. Iynedjian PB (2009) Molecular physiology of mammalian glucokinase. Cell Mol Life Sci 66: 27-42.
18. Massa ML, Gagliardino JJ, Francini F (2011) Liver glucokinase: An overview on the regulatory mechanisms of its activity. IUBMB Life 63: 1-6.
19. Velho G, Petersen KF, Perseghin G, Hwang JH, Rothman DL, et al. (1996) Impaired hepatic glycogen synthesis in glucokinase-deficient (MODY-2) subjects. J Clin Invest 98: 1755-1761. (Pubitemid 26359191)
20. Magnuson MA, Andreone TL, Printz RL, Koch S, Granner DK (1989) Rat glucokinase gene: structure and regulation by insulin. Proc Natl Acad Sci U S A 86: 4838-4842.
21. van Schaftingen E, Vandercammen A, Detheux M, Davies DR (1992) The regulatory protein of liver glucokinase. Adv Enzyme Regul 32: 133-148.
22. Caro JF, Triester S, Patel VK, Tapscott EB, Frazier NL, et al. (1995) Liver glucokinase: decreased activity in patients with type II diabetes. Horm Metab Res 27: 19-22.
23. Torres TP, Catlin RL, Chan R, Fujimoto Y, Sasaki N, et al. (2009) Restoration of hepatic glucokinase expression corrects hepatic glucose flux and normalizes plasma glucose in zucker diabetic fatty rats. Diabetes 58: 78-86.
24. O'Doherty RM, Lehman DL, Telemaque-Potts S, Newgard CB (1999) Metabolic impact of glucokinase overexpression in liver: lowering of blood glucose in fed rats is accompanied by hyperlipidemia. Diabetes 48: 2022-2027. (Pubitemid 29458366)
25. Beer NL, Tribble ND, McCulloch LJ, Roos C, Johnson PR, et al. (2009) The P446L variant in GCKR associated with fasting plasma glucose and triglyceride levels exerts its effect through increased glucokinase activity in liver. Hum Mol Genet 18: 4081-4088.
26. Kozian DH, Barthel A, Cousin E, Brunnhofer R, Anderka O, et al. (2010) Glucokinase-activating GCKR polymorphisms increase plasma levels of triglycerides and free fatty acids, but do not elevate cardiovascular risk in the Ludwigshafen Risk and Cardiovascular Health Study. Horm Metab Res 42: 502-506.
27. Dupuis J, Langenberg C, Prokopenko I, Saxena R, Soranzo N, et al. (2010) New genetic loci implicated in fasting glucose homeostasis and their impact on type 2 diabetes risk. Nat Genet 42: 105-116.
28. Eiki J, Nagata Y, Futamura M, Sasaki-Yamamoto K, Iino T, et al. (2011) Pharmacokinetic and pharmacodynamic properties of the glucokinase activator MK-0941 in rodent models of type 2 diabetes and healthy dogs. Mol Pharmacol 80: 1156-1165.
29. Futamura M, Yao J, Li X, Bergeron R, Tran JL, et al. (2012) Chronic treatment with a glucokinase activator delays the onset of hyperglycaemia and preserves beta cell mass in the Zucker diabetic fatty rat. Diabetologia 55: 1071-1080.
30. De Ceuninck F, Kargar C, Ilic C, Caliez A, Rolin JO, et al. (2013) Small molecule glucokinase activators disturb lipid homeostasis and induce fatty liver in rodents: a warning for therapeutic applications in humans. Br J Pharmacol 168: 339-353.
31. Waring MJ, Brogan IJ, Coghlan M, Johnstone C, Jones HB, et al. (2011) Overcoming retinoic acid receptor-α based testicular toxicity in the optimisation of glucokinase activators. Med Chem Commun 2: 771-773.
32. Pfefferkorn JA, Guzman-Perez A, Litchfield J, Aiello R, Treadway JL, et al. (2012) Discovery of (S)-6-(3-cyclopentyl-2-(4-(trifluoromethyl)-1H-imidazol- 1-yl)propanamido)nicotini c acid as a hepatoselective glucokinase activator clinical candidate for treating type 2 diabetes mellitus. J Med Chem 55: 1318-1333.
33. Kazierad DJ, Pfefferkorn JA, Bergman A, Wang X, Rolph TP, et al. (2013) The Hepatoselective Glucokinase Activator (GKA) PF-04991532, Lowers HbA1c after 12-Weeks of Dosing in Patients with Type 2 Diabetes (T2DM). 73rd American Diabetes Conference, Chicago, IL.
34. Kazierad DJ, Bergman A, Pfefferkorn JA, Wang X, Rolph TP, et al. (2013) Pharmacokinetics (PK) and pharmacodynamics (PD) of PF-04991532, a hepatoselective glucokinase activator (GKA), administered as monotherapy in Japanese and Non-Japanese T2DM Patients. 73rd American Diabetes Conference, Chicago, IL.
35. Nissim I, Horyn O, Nissim I, Daikhin Y, Wehrli SL, et al. (2012) Effects of a glucokinase activator on hepatic intermediary metabolism: study with 13C-isotopomer-based metabolomics. Biochem J 444: 537-551.
36. Peter A, Stefan N, Cegan A, Walenta M, Wagner S, et al. (2011) Hepatic glucokinase expression is associated with lipogenesis and fatty liver in humans. J Clin Endocrinol Metab 96: E1126-1130.
37. Cool B, Zinker B, Chiou W, Kifle L, Cao N, et al. (2006) Identification and characterization of a small molecule AMPK activator that treats key components of type 2 diabetes and the metabolic syndrome. Cell Metab 3: 403-416. (Pubitemid 43811782)
38. Healey EC, O'Brien TP, McCoy GA, Farmer TD, Erion DM, et al. (2013) Chronic dosing of a liver-specific glucokinase activator decreases fasting hyperglycemia by decreasing hepatic glucose production in Zucker diabetic rats.
39. Winzell MS, Coghlan M, Leighton B, Frangioudakis G, Smith DM, et al. (2011) Chronic glucokinase activation reduces glycaemia and improves glucose tolerance in high-fat diet fed mice. Eur J Pharmacol 663: 80-86.
40. Coghlan M, Leighton B (2008) Glucokinase activators in diabetes management. Expert Opin Investig Drugs 17: 145-167. (Pubitemid 351578197)
41. Kim JB, Sarraf P, Wright M, Yao KM, Mueller E, et al. (1998) Nutritional and insulin regulation of fatty acid synthetase and leptin gene expression through ADD1/SREBP1. J Clin Invest 101: 1-9. (Pubitemid 28058896)
42. Shimomura I, Bashmakov Y, Ikemoto S, Horton JD, Brown MS, et al. (1999) Insulin selectively increases SREBP-1c mRNA in the livers of rats with streptozotocin-induced diabetes. Proc Natl Acad Sci U S A 96: 13656-13661.
43. Berry MN, Friend DS (1969) High-yield preparation of isolated rat liver parenchymal cells: a biochemical and fine structural study. J Cell Biol 43: 506-520.
44. Aiello RJ, Kenna TM, Herbein JH (1984) Hepatic gluconeogenic and ketogenic interrelationships in the lactating cow. J Dairy Sci 67: 1707-1715.
45. Mills SE, Armentano LE, Russell RW, Young JW (1981) Rapid and specific isolation of radioactive glucose from biological samples. J Dairy Sci 64: 1719-1723.
46. Rossetti L, Smith D, Shulman GI, Papachristou D, DeFronzo RA (1987) Correction of hyperglycemia with phlorizin normalizes tissue sensitivity to insulin in diabetic rats. J Clin Invest 79: 1510-1515. (Pubitemid 17099657)
47. Rossetti L, Giaccari A, Barzilai N, Howard K, Sebel G, et al. (1993) Mechanism by which hyperglycemia inhibits hepatic glucose production in conscious rats. Implications for the pathophysiology of fasting hyperglycemia in diabetes. J Clin Invest 92: 1126-1134. (Pubitemid 23273883)
48. Smith D, Rossetti L, Ferrannini E, Johnson CM, Cobelli C, et al. (1987) In vivo glucose metabolism in the awake rat: tracer and insulin clamp studies. Metabolism 36: 1167-1174.
49. Folch J, Lees M, Sloane Stanley GH (1957) A simple method for the isolation and purification of total lipides from animal tissues. J Biol Chem 226: 497-509.
50. Kaluzny MA, Duncan LA, Merritt MV, Epps DE (1985) Rapid separation of lipid classes in high yield and purity using bonded phase columns. J Lipid Res 26: 135-140. (Pubitemid 15133302)
51. Shulman GI, Ladenson PW, Wolfe MH, Ridgway EC, Wolfe RR (1985) Substrate cycling between gluconeogenesis and glycolysis in euthyroid, hypothyroid, and hyperthyroid man. J Clin Invest 76: 757-764.
52. Wu Z, Irizarry RA (2004) Preprocessing of oligonucleotide array data. Nat Biotechnol 22: 656-658; author reply 658.
53. Smyth GK (2004) Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol 3: Article3.
54. Benjamini Y, Drai D, Elmer G, Kafkafi N, Golani I (2001) Controlling the false discovery rate in behavior genetics research. Behav Brain Res 125: 279-284. (Pubitemid 33000466)